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We constructed a double-stranded plasmid containing
a single cis,syn-cyclobutane thymine dimer (T[c,s]T) 385
base pairs from the center of the SV40 origin of replica-
tion. This circular DNA was replicated in vitro by ex-
tracts from several types of human cells. The dimer was
placed on the leading strand template of the first repli-
cation fork to encounter the lesion. Two-dimensional gel
electrophoresis of replication intermediates docu-
mented the transient arrest of the replication fork by
the dimer. Movement of the replication fork beyond the
dimer was recognized by the appearance of a single fork
arc in DNA sequences located between the T[c,s]T and
the half-way point around the circular template (180°
from the origin). Upon completion of plasmid replica-
tion, the T[c,s]T was detected by T4 endonuclease V in
about one-half (46 6 9%) of the closed circular daughter
molecules. Our results demonstrate that extracts pre-
pared from HeLa cells and SV40-transformed human
fibroblasts (SV80, IDH4), including a cell line defective
in nucleotide-excision repair (XPA), were competent for
leading strand DNA synthesis opposite the pyrimidine
dimer and replication fork bypass. In contrast, dimer
bypass was severely impaired in otherwise replication-
competent extracts from two different xeroderma pig-
mentosum variant cell lines.
Solar ultraviolet radiation is a ubiquitous environmental
carcinogen responsible for 500,000 or more new cases of skin
cancer in the United States each year (1, 2). Exposure of human
cells to natural sunlight leads to the formation of cyclobutane
pyrimidine dimers (CPDs),1 pyrimidine(6–4)pyrimidone
dimers, and their Dewar valence isomers (3). UV-induced DNA
photoproducts are currently accepted as important underlying
factors in skin carcinogenesis (2, 4). Studies with UVC (254
nm), which forms predominantly CPDs (70–80%) and 6–4
dimers (20–30%), have indicated that mutations and chromo-
somal aberrations are induced when human cells attempt to
replicate the damaged DNA (5, 6). Therefore, the mechanisms
whereby human cells complete the replication of template
strands containing photoproducts are of considerable interest.
UVC inhibits DNA replication in diploid human fibroblast
strains by a variety of mechanisms, including G1 arrest (6) and
inhibition of replicon initiation in S phase cells (7). These two
checkpoint responses appear to be protective processes, provid-
ing more time for DNA repair to remove photoproducts before
DNA replication. UVC also induces inhibition of DNA synthe-
sis in active replicons (7, 8). The latter is thought to reflect, at
least in part, the stalling of DNA replication forks at pyrimi-
dine dimers (9–11), perhaps due to a reduced capacity of DNA
polymerases to incorporate DNA precursors into nascent
strands opposite template lesions (12–15). This inhibition, how-
ever, is not absolute, and bypass replication eventually takes
place, as evidenced by the generation of replicated DNA con-
taining photoproducts and the induction of point mutations at
dipyrimidine sites. UV-induced mutations in the p53 tumor
suppressor gene in non-melanoma skin cancers are character-
ized by a high proportion of C 3 T transitions (16–18). Base
substitution mutations at thymines do not occur with high
frequency in UV-damaged genes that are replicated at their
natural chromosomal locations (19) or as part of shuttle vectors
(20–22).
Previous studies have demonstrated that protein extracts
from HeLa cells are capable of replicating past CPDs during in
vitro replication of UV-damaged plasmids carrying the SV40
origin of replication (23–26). Experimental evidence in support
of this conclusion was found primarily by probing for the pres-
ence of sites sensitive to nicking by the CPD-specific enzyme,
T4 endonuclease V (T4 endoV), in replicated (DpnI-resistant),
closed circular DNA molecules (23–26). In addition, UV-in-
duced mutagenesis at dipyrimidine sites of randomly damaged
plasmids (almost exclusively C 3 T) presumably reflected er-
ror-prone bypass replication (trans-lesion synthesis) of CPDs
(23, 24).
Bypass replication of a single dimer strategically placed on
one or the other anti-parallel strand of DNA has also been
examined (25, 26). Inference as to whether bypass replication
occurred via leading or lagging strand synthesis was made on
the basis of the location and orientation of the dimer, vis à vis
the SV40 origin of replication, and the probability of first en-
counter of the CPD by one or the other of the replication forks
moving in opposite direction around the circular molecule. By
measuring the relative synthesis of complementary strands at
restriction fragments spanning the dimer or located immedi-
ately downstream, Svoboda and Vos (25) have concluded that
when the pyrimidine dimer is on the template to the leading
strand the synthesis of the latter is interrupted, but the syn-
thesis of the lagging strand continues, presumably by displace-
ment of the replication fork beyond the lesion. In this study, we
have analyzed by two-dimensional gel electrophoresis the to-
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pology of replicating molecules to map the displacement of
DNA replication forks, in relationship to the position of the
CPD, and to demonstrate directly the capability for leading
strand bypass replication in human cells. Carty et al. (26) have
recently reported that in vitro bypass replication of a single TT
site containing either a CPD or a 6–4 dimer is poorly
mutagenic.
Studies of the familial skin cancer syndrome, xeroderma
pigmentosum, have revealed a form of the disease, in which a
major biochemical defect in nucleotide excision repair (NER)
was not detected, hence the designation of this group as variant
(27–31). The defining feature of this unique xeroderma pigmen-
tosum group is the abnormal semi-conservative replication of
UV-damaged DNA (7, 8, 31–34). The high risk of cancer in
sun-exposed skin (35, 36) and the enhanced sensitivity to UV-
induced transformation (37, 38) and mutagenesis (39–43) sup-
port the hypothesis that xeroderma pigmentosum variant
(XPV) cells have lost a gene product that participates in an
essentially error-free pathway of replication of DNA containing
pyrimidine dimers. Our results demonstrate that replication-
competent extracts from XPV cells are deficient in the bypass of
CPDs, under conditions in which other human cell extracts are
capable of catalyzing this process.
EXPERIMENTAL PROCEDURES
Materials
M13mp2SV was a gift from Dr. Thomas A. Kunkel (NIEHS). Prepa-
rations of T4 endoV were provided by Dr. Isabel Mellon (University of
Kentucky) and Dr. Stephen Lloyd (University of Texas Medical Branch
at Galveston). The oligonucleotide containing the single T[c,s]T dimer
was a gift from Dr. Aziz Sancar (University of North Carolina, Chapel
Hill). Undamaged oligonucleotides were synthesized by the Nucleic
Acids Core Facility of the Lineberger Comprehensive Cancer Center.
Eagle’s minimal essential medium and L-glutamine were purchased
from Life Technologies, Inc. Fetal bovine serum was obtained from
HyClone Laboratories Inc. (Logan, UT), and gentamicin came from
Elkins-Sinn Inc. (Cherry Hill, NJ). HeLa S3 cells were obtained from
the Lineberger Comprehensive Cancer Center Tissue Culture Facility
(University of North Carolina, Chapel Hill). Polynucleotide kinase,
DNA polymerase, and DNA ligase from bacteriophage T4, as well as
restriction enzymes and DNA polymerase I (Klenow fragment used to
end label pUC19), were purchased from Boehringer Mannheim. The
supplier of purified SV40 large T antigen was Molecular Biology Re-
sources, Inc. (Milwaukee, WI). [a-32P]dCTP (.3000 Ci/mmol) was from
Amersham Life Sciences, and unlabeled nucleotides were from Phar-
macia Biotech Inc. Creatine phosphate, creatine phosphokinase, and
proteinase K were from Sigma.
Methods
Cell Lines, Culture Conditions, and Preparation of Cell-free Ex-
tracts—The SV40-transformed cell lines used in this study were derived
from XPV fibroblasts, XP4BE (CTag, Ref. 44), and XP30RO (XP30RO/
9.8, Ref. 45); XPA fibroblasts (XP12BE, GM4429, NIGMS Human Ge-
netic Mutant Cell Repository); and other human fibroblasts (SV80, Ref.
46, and IDH4, Ref. 47). Monolayer cultures were grown in Eagle’s
minimal essential medium supplemented with 10% fetal bovine serum,
2 mM L-glutamine, and 50 mg/ml gentamicin in an atmosphere of 5%
CO2 at 37 °C. Extracts were prepared according to published protocols
(48, 49).
Construction of M13leaSV Containing a Single T[c,s]T Dimer—The
sequence 59-GAGCTCAATTAGTCAGCTGC-39 was introduced into the
lacZa sequence of M13mp2SV (50) by site-directed mutagenesis (51).
This insertion created a unique XhoI and an additional PvuII recogni-
tion site in this new construct (M13leaSV, see Fig. 1). Double-stranded,
closed circular DNA molecules containing a single pyrimidine dimer
were synthesized by annealing closed circular, single-stranded
M13leaSV DNA (1 strand), with the oligonucleotide 39-CTCGAG
(T[c,s]T)AATCAGTCGACG-59, previously phosphorylated at the 59-end
using T4 polynucleotide kinase. This was followed by second-strand
synthesis, ligation, and purification in CsCl density gradients, accord-
ing to published procedures (52). Undamaged DNA controls included
RFI of M13leaSV or molecules prepared as described above but using an
oligonucleotide without the dimer.
In Vitro DNA Replication—Reactions of 25 or 50 ml contained 30 mM
Hepes, pH 7.8, 7 mM MgCl2, 4 mM ATP, 200 mM each of the other three
rNTPs, 100 mM each of the four dNTPs, 100–150 mCi/ml [a-32P]dCTP,
40 mM creatine phosphate, 100 mg/ml creatine phosphokinase, 15 mM
sodium phosphate, pH 7.5, 1.6 mg/ml M13leaSV DNA, 40 mg/ml SV40
large T antigen (Tag), 4 mg/ml proteins from human cell extracts (49).
Reaction mixtures without Tag were used as negative controls. After
incubation at 37 °C for different periods, the reactions were terminated
by adding an equal volume of stop solution containing 2% SDS, 2 mg/ml
proteinase K, and 50 mM EDTA. In those experiments in which the goal
was to quantify specific DNA products fractionated by single dimension
agarose gel electrophoresis, an identical amount of linear pUC19 DNA
(end-labeled with [a-32P]dCTP by in vitro polymerization at the HindIII
cut site) was also added to each reaction. Replication products were
purified by one or two extractions with an equal volume of a 1:1 (v/v)
mixture of phenol and chloroform/isoamyl alcohol (24:1 v/v), followed by
a final extraction with chloroform/isoamyl alcohol and then ethanol
precipitation. DNA was routinely dissolved in 10 mM Tris, 1 mM EDTA,
pH 7.5, and fractionated in 1% agarose gels containing 0.2 mg/ml
ethidium bromide. Dried gels were analyzed with an AMBIS Image
Acquisition & Analysis system (AMBIS, Inc., San Diego, CA) or exposed
to a phosphor screen that was later scanned by a PhosphorImager™
(Molecular Dynamics, Sunnyvale, CA).
T4 Endonuclease V Assay—DNA replication products from either
control or T[c,s]T dimer-containing templates were purified as above
and incubated in the presence or absence of T4 endoV. The enzyme
preparation received from Dr. Isabel Mellon (485 mg/ml; 2.7 3 1010
nicks/min/ml) was used without dilution at 1 ml per 20-ml reaction
containing in vitro replication products in 100 mM NaCl, 10 mM EDTA,
10 mM Tris-HCl, pH 8.0, and 1 mg/ml bovine serum albumin. These
reactions were incubated for 1 h at 37 °C. The T4 endoV received from
Dr. Stephen Lloyd (stock solution at ;150 mg/ml) was first diluted 250
or 1000 times in reaction buffer. DNA replication products in 25 mM
NaH2PO4, pH 6.8, 1 mM EDTA, 100 mM NaCl, 100 mg/ml bovine serum
albumin were mixed with 1 ml of the diluted T4 endoV and incubated at
37 °C for 30 min. Reactions were terminated by adding one-fifth final
volume of a solution containing 50% glycerol, 0.04% bromphenol blue,
and 10% SDS. Subsequent to electrophoresis, the dried gels were ana-
lyzed as above.
Two-dimensional Agarose Gel Electrophoresis (53, 54)—DNA repli-
cation products were purified from 30-min reactions and digested with
the indicated restriction enzyme(s). Electrophoresis was first carried
out at 0.4 V/cm for approximately 68 h in 0.4% agarose gels prepared in
45 mM Tris borate, 1 mM EDTA (TBE), also containing 0.2 mg/ml
ethidium bromide. Excised lanes were cast into a second gel containing
1% agarose and 0.2 mg/ml ethidium bromide in TBE. The second elec-
trophoresis, at a 90° angle with respect to the first, was run at 1.5 V/cm
for approximately 24 h. The dried gels were exposed to a phosphor
screen and scanned by a PhosphorImager™.
Quantification of DNA Synthesis from AMBIS™ or Phosphor
Imager™ Files—AMBIS QuantProbe Software or ImageQuaNT™ (Mo-
lecular Dynamics) was used to determine the amount of radioactivity
associated with DNA by volume integration of defined regions of the
scanned images. Objects were drawn with the rectangle or polygon tool
to closely surround the areas of interest. In single dimensional gel
electrophoresis analyses, all DNA species were included within a single
object for the measurement of total DNA synthesis; specific forms (e.g.
RFI and RFII) were quantified individually. Lane specific background
was defined by a rectangle drawn under the pUC19 band. Integrated
volumes (net counts) were then normalized to pUC19 recovered in each
lane.
In experiments in which we incubated DNA with T4 endoV prior to
gel electrophoresis, we noticed that we systematically lost a small
fraction of the radiolabel incorporated at the ends of the linearized
pUC19 molecules. Since this internal standard was added to each
sample at the end of the in vitro replication reaction, the control (no
enzyme addition) and treated samples contained the same ratio of total
replication products to pUC19. We calculated this ratio for control
samples and estimated the volume of pUC19 from the volume of total
replication products for lanes containing T4 endoV. Then, this esti-
mated volume of the internal standard was used to normalize the
relative units of precursor incorporation in RFI and RFII.
Analyses of the two-dimensional gel electrophoresis images acquired
with the PhosphorImager™ were done with the polygon tool and Im-
ageQuaNT™. Only replication-intermediate arcs were quantified; vol-
ume integration was done with no background correction. The inte-
grated volumes of bubble and fork arcs were expressed as percentages
of the sum of all replicating structures detected in each image. The
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percentage distribution determined with the dimer-containing molecule
was compared with that observed with the undamaged DNA.
RESULTS
Construction of M13leaSV Containing a Single T[c,s]T
Dimer—Fig. 1 shows the position of the cis,syn-cyclobutane
thymine dimer relative to the SV40 origin of replication in the
double-stranded and closed circular molecule (7.4 kb) that was
used as the site-specifically damaged substrate in the in vitro
replication assays described below. These assays are dependent
on Tag-directed initiation of replication at the SV40 origin and
semi-conservative DNA synthesis (55) by two replication forks
moving away from the origin in opposite directions (bi-direc-
tional replication). Note that in this construct, the replication
fork moving from the origin toward the single EcoRI recogni-
tion site encounters the pyrimidine dimer (T[c,s]T) on the tem-
plate to the leading strand of nascent DNA, 385 bp from the
center of the SV40 origin of replication (Fig. 1).
In Vitro DNA Replication—Dimer-containing and undam-
aged plasmids were replicated in vitro with extracts from hu-
man cells. Radiolabeled products were analyzed for the degree
of inhibition of RFI synthesis by the pyrimidine dimer and to
determine whether the T[c,s]T was present in the newly syn-
thesized, closed circular DNA molecules. In this experimental
system, the generation of dimer-containing RFI DNA could
proceed along two potentially distinct pathways (Fig. 2). If the
dimer blocks one of the forks, at least momentarily (Fig. 2A),
the other replication fork displacing in the opposite direction
could complete synthesis around the circular DNA. This would
generate an RFI from the undamaged strand and potentially
leave the dimer in a gapped molecule. Following segregation of
the daughter molecules, it is conceivable that other activities,
such as gap-filling repair, could be responsible for completing
synthesis across the pyrimidine dimer to form the dimer-con-
taining RFI. Fig. 2B depicts the displacement of the right
replication fork up to and beyond the pyrimidine dimer, thus
catalyzing bypass replication, presumably by extension of the
leading strand. As both pathways depicted in Fig. 2 could be
operational during in vitro replication, it would be premature
to conclude how bypass replication has taken place only from
the position and orientation of the dimer in relationship to the
origin of replication. Therefore, it became imperative to distin-
guish which pathway was more likely to be followed during
replication of damaged DNA molecules in vitro, to investigate
potential mechanisms of dimer bypass and later evaluate bio-
logical consequences of placing the lesion on the template to the
leading or lagging strand of nascent DNA.
Fig. 3 illustrates the fractionation of in vitro replication
products from reactions in which dimer-containing and control
DNA were incubated with extracts from HeLa cells or XPV
(CTag) fibroblasts. Results with extracts from other human
fibroblasts are shown in Fig. 4. The amounts of total DNA
replication products and RFI were estimated from their radio-
activity (AMBIS™ or PhosphorImage™ units) after normaliza-
tion to the internal standard (pUC19). Total DNA synthesis
using the HeLa extract was not inhibited by the dimer. DNA
synthesis on the damaged molecule averaged 98 6 27%
(mean 6 S.D., n 5 20) that on the undamaged molecule in
experiments in which the incubation time varied from 1 to 6 h.
In contrast, total DNA synthesis on the damaged molecule
using the CTag extract was 69 6 23% control (n 5 15, p , 0.01,
CTag versus HeLa, Student’s t test). Synthesis of RFI DNA
from the dimer-containing substrate was severely reduced in
the CTag extract (27 6 9%, n 5 15) in comparison to HeLa
(72 6 22%, n 5 19), and this difference was highly significant
FIG. 1. Construction of M13leaSV containing a single T[c,s]T
dimer. The diagram indicates where the dimer was placed on the
template to the leading strand, relative to the SV40 origin of replication
(ORI). M13leaSV sequence was numbered by designating as nucleotide
number 1 the last G of the BglI site at the SV40 origin. The position of
recognition sites for the enzymes used in this study are also noted
(coordinates are given in parentheses). A control plasmid was con-
structed with an identical oligonucleotide, except for the absence of the
photoproduct.
FIG. 2. Potential effects of the T[c,s]T dimer on the in vitro
synthesis of RFI DNA. The dimer (TT) was placed on the template to
the leading strand of nascent DNA synthesized by the replication fork
moving to the right of the SV40 origin of replication (O). The diagram
illustrates two scenarios as follows: A, complete blockage of both lead-
ing strand synthesis and displacement of the replication fork, and B,
bypass of the TT dimer by the right fork. RFI DNA containing the dimer
could be generated via pathway B or via pathway A if DNA synthesis by
the left fork is followed by gap-filling.
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(p , 0.005). Thus, by two different measures of DNA synthesis,
extracts from XPV cells were impaired relative to HeLa in their
capacity to replicate a circular DNA molecule that contained a
single pyrimidine dimer. Experiments with extracts from
SV40-transformed fibroblasts (IDH4, SV80, XPA) yielded re-
sults that were comparable to those described for HeLa ex-
tracts. In the experiments illustrated in Fig. 4, for example,
RFI synthesis from the T[c,s]T-containing molecules repre-
sented 86% (IDH4), 78% (SV80), and 53% (XPA) that deter-
mined with the undamaged control.
Bypass Replication of the T[c,s]T Dimer—RFI that contains a
CPD is nicked by T4 endoV and converted to RFII with reduced
electrophoretic mobility. By measuring the fraction of newly
synthesized RFI DNA that is resistant to nicking by T4 endoV,
one can calculate the fraction that carries the dimer (fraction
sensitive to nicking). We determined that 0.43 6 0.03 (n 5 5)
corresponded to the fraction of RFI DNA, produced during in
vitro reactions (1.5 to 6 h) with the HeLa extract, that was
nicked by T4 endoV (Fig. 3 and Table I). Under identical con-
ditions, the nicked fraction of RFI synthesized from undam-
aged DNA by the same extract was 0.09 6 0.08 (n 5 5). By
correcting for this background we found that 34% of the RFI
DNA synthesized from the T[c,s]T-containing template by
HeLa carried the dimer (theoretical maximum of 50%). Similar
calculations with the data depicted in Fig. 4 revealed the pres-
ence of the dimer in 45, 52, and 54% of the RFI molecules newly
synthesized by IDH4, SV80, and XPA extracts, respectively
(Table I). In contrast, the small amount of RFI synthesized by
the XPV (CTag) extract from the damaged molecule (Fig. 3)
demonstrated the same sensitivity to nicking by T4 endoV as
the RFI products from undamaged DNA (Table I). We inter-
preted these results as evidence that the CTag extract was
unable to complete synthesis of the template strand containing
the pyrimidine dimer. Similar results were also obtained with
XP30RO extracts (not shown).
We envision that the replication of T[c,s]T-containing DNA
by the CTag extract followed the sequence of events illustrated
on Fig. 2A. Absence of gap-filling repair activity could explain
the T4 endoV results obtained with the XPV extract. Accord-
ingly, if the same path is followed by all the replicating T[c,s]T-
molecules in the HeLa extract, the presence of the dimer in RFI
molecules would suggest that these extracts are competent to
support some type of gap-filling process in vitro. Fig. 2B pre-
dicts an alternative pathway in which the complete replication
of the T[c,s]T-containing DNA follows the bypass of the dimer
by the right fork, the first one to encounter the lesion, thus
generating one RFI containing the dimer and one RFI from the
undamaged strand (50% of the RFI molecules would be sensi-
tive to nicking by T4 endoV). Consider that in one-half of the
replicating molecules the dimer is bypassed by the right fork
(Fig. 2B), and in the other half replication is completed around
the circular DNA while the right fork is still blocked at the
lesion (Fig. 2A). Then, in the absence of gap-filling repair the
expected fraction of RFI containing the dimer would be 0.33.
Results of dimer-dependent nicking by T4 endoV of RFI DNA
synthesized by the HeLa extract (see above) are consistent with
this prediction.
Topology of Intermediates of DNA Replication—To determine
whether the synthesis of RFI DNA carrying the T[c,s]T dimer
was the product of elongation of the leading strand and repli-
cation fork bypass, or gap-filling repair, we analyzed the topol-
ogy of intermediates of DNA replication by two-dimensional gel
electrophoresis (53, 54) and deduced the position of the repli-
cation forks relative to the pyrimidine dimer. The probability of
the unblocked fork moving around the circular molecule and
rescuing the blocked fork (Fig. 2A) was reduced by decreasing
to 30 min the incubation time for the in vitro replication reac-
tions. After this short incubation, the labeling associated with
RFI DNA represented only 3–5% of the total Tag-dependent
products of replication (results not shown), when undamaged
molecules were replicated with HeLa or CTag extracts, and
even less when HeLa (;2%) or CTag (none detected) extracts
were used to replicate the damaged plasmid. Data illustrated
FIG. 4. Extracts from human fibroblasts support the replica-
tion of T[c,s]T-containing plasmids, regardless of their NER
capability. Template molecules containing the T[c,s]T dimer (lanes 1,
2, 5, 6, 9, and 10) or not (control in lanes 3, 4, 7, 8, 11, and 12) were
replicated in vitro during 2-h reactions with extracts from fibroblasts
that are endowed with wild-type activity for NER (IDH4, lanes 1–4;
SV80, lanes 5–8) or are defective in this process (XPA, NER-mutant,
lanes 9–12). DNA was purified and incubated in the presence (1) or
absence (2) of T4 endoV, as described under “Methods.”
FIG. 3. Dimer-dependent inhibition of in vitro DNA replication
and RFI sensitivity to nicking by T4 endoV. Extracts from XPV
(CTag) and HeLa cells were incubated with control or T[c,s]T-contain-
ing template and [a-32P]dCTP for 2, 4, and 6 h in the presence of Tag.
As an internal standard, 32P-pUC19 was added to the products of
replication, which were then purified and separated by agarose gel
electrophoresis. The positions of RFI, RFII, and pUC19 are indicated.
For the purpose of generating this illustration, the dried gel was ex-
posed to an x-ray film and the autoradiograph was scanned with a
Pixelcraft ProImager 4000. The computer images were labeled with the
color software Photoshop 3.0 in a Macintosh Power PC 8100 with
system 7.0.1 and printed with a FUJIX Pictography 3000. Relative
levels of RFI, as measured by the ratios of RFI/pUC19, are given below
for each of the lanes in the same sequence as they appear in the figure:
3.5, 2.9, 2.6, 3.3, 2.8, 2.3, 0.56, 0.76, 0.98, 0.49, 0.74, 1.1 (A); and 2.9, 5.8,
3.2, 2.9, 5.8, 2.8, 3.1, 3.6, 3.9, 1.9, 2.0, 2.1 (B). In the same manner,
values for total DNA synthesis, as reflected by the ratios of total
products over pUC19, were as follows: 17, 27, 26, 15, 26, 25, 10, 16, 16,
9, 14, 15 (A); and 29, 45, 44, 30, 48, 47, 28, 43, 51, 28, 43, 47 (B).
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in Fig. 5 confirmed that during the 30-min incubation there
was insufficient time for the unblocked fork to approach the
pyrimidine dimer from the opposite direction. Upon digestion
with AlwNI, a restriction enzyme with a single recognition site
;180° from the SV40 origin (Fig. 1), the replication interme-
diates behaved in the two-dimensional gels as a family of
molecules containing replication bubbles of various sizes. Note
that the extension of the bubble arc was slightly reduced in the
samples containing the damaged template (Fig. 5, B and D), as
compared with the undamaged control (Fig. 5, A and C). Most
remarkable, however, was the absence of a double fork arc in
Fig. 5, B and D. If the replication fork expanding away from the
dimer had been displaced beyond the AlwNI site (Fig. 1), and
the other fork was stalled at the CPD (Fig. 2A), enzyme diges-
tion of these partially replicated molecules would occur within
the replication bubble and generate molecules containing a
large fork at one end and a smaller one at the other. If these
double fork molecules were present, they would generate a
distinct arc (Fig. 5, E and F), separable from that displayed by
the bubble-containing molecules (53, 54), as illustrated in Fig.
5, G and H.
The progression of the replication fork traveling up to and
beyond the pyrimidine dimer on the right side was monitored
by digesting the replicating molecules with ClaI. This restric-
tion enzyme cuts M13leaSV at two different positions, 677 bp
beyond the T[c,s]T dimer and about 180° from the SV40 origin
of replication (Figs. 1 and 2). Thus, ClaI digestion of this
circular DNA molecule produced fragments of 4.5- and 2.9-kb
in length, with the SV40 origin of replication located off-center
in the 4.5-kb fragment (Fig. 6D). Accordingly, two-dimensional
gel electrophoresis of products from the undamaged substrate
revealed two families of intermediates of replication, both as-
sociated with the 4.5-kb fragment, but with two distinct topol-
ogies (compare diagrams in Figs. 2 and 6D). One family mi-
grated in the two-dimensional gels as a bubble arc because the
right fork had not yet reached the ClaI site closest to the SV40
origin. Subsequent to the replication of this ClaI site, the 4.5-kb
replicating fragments migrated along a single fork (SF) arc.
This led also to the simultaneous appearance of a distinct SF
arc in association with the 2.9-kb fragment (Fig. 6, B, E, and
H). Note that the amount of radioactivity associated with each
one of the replication arcs is a function of the number of
replicating molecules, the length of the fragment, and how
much of it has been replicated (i.e. incorporated radiolabeled
DNA precursors). We detected equivalent distributions of ra-
dioactivity in these three arcs of replicative structures when
undamaged molecules were replicated with extracts from HeLa
(Fig. 6B), IDH4 (Fig. 6E), CTag (Fig. 6H), or XPA (Fig. 7A),
suggesting that displacement rates of replication forks were
very similar in replication-competent extracts from these four
types of cells. This finding supports the conclusion that CTag
extracts do not lack any of the basic components of the enzy-
matic machinery that catalyzes the semi-conservative replica-
tion of undamaged DNA.
Strikingly different results were obtained when the T[c,s]T-
containing DNA was replicated in vitro. Fig. 6, C and F, clearly
shows SF arcs in association with the 2.9-kb fragment from
DNA replicated with extracts from HeLa or the SV40-trans-
formed normal fibroblast (IDH4), albeit less intense than those
observed with the undamaged template in Fig. 6, B and E,
respectively. However, no SF arc was detected in association
with the 2.9-kb fragment when the damaged molecule was
replicated by extracts from XPV cells (CTag, Fig. 6I). This
result also demonstrated that our preparations of T[c,s]T-con-
taining DNA were devoid of detectable contamination with
undamaged molecules. Furthermore, data from experiments in
the absence of Tag (Fig. 6, A and G) indicate that the radioac-
tivity detected in the 2.9-kb linear fragment (Fig. 6I) was not
incorporated via DNA replication. Instead, it appears to reflect
random incorporation of [32P]dCMP, as evidenced by the label-
ing of the two ClaI linear fragments in the absence of any arcs
of replicating intermediates (Fig. 6, A and G). Results identical
to those displayed in Fig. 6, H and I, were obtained with
extracts from SV3CRL9.7, another immortalized clone of
XP4BE (44), and XP30RO/9.8, a cell line from a different XPV
patient (45). Thus, bypass replication of the pyrimidine dimer
by extracts from three different XPV cell lines (two independ-
ent patients) was undetectable, under the experimental condi-
TABLE I
T4 endonuclease V-sensitive sites in RFI DNA synthesized in vitro
DNA products of in vitro replication were incubated with T4 endoV to determine the fraction of RFI molecules containing the T[c,s]T
(dimer-dependent nicked fraction). The amount of RFI remaining after treatment (normalized to the internal standard) was divided by the amount
of RFI in identical samples incubated in the absence of the enzyme. This ratio (T4 endonuclease V-resistant fraction) was subtracted from 1 to











A. HeLa 1.5 0.17 0.43 0.26
2.0 0.00 0.39 0.39
3.0 0.16 0.44 0.28
4.0 0.00 0.44 0.44
6.0 0.13 0.46 0.33
Mean 6 SD, 0.09 6 0.08 0.43 6 0.03 0.34 6 0.07
B. IDH4 2.0 0.10 0.55 0.45
C. SV80 2.0 0.00 0.52 0.52
D. XPA 2.0 0.00 0.54 0.54
E. XPV (CTag) 1.5 0.03 0.13 0.10
2.0 0.06 0.13 0.07
3.0 0.15 0.14 20.01
4.0 0.03 0.03 0.00
6.0 0.12 0.00 20.12
Mean 6 SD, 0.08 6 0.05 0.09 6 0.07 0.01 6 0.08
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tions used in this study. On the other hand, extracts from
NER-deficient cells (XPA) displayed capability for bypass rep-
lication of CPDs by the T4 endoV assay (Fig. 4) and the two-
dimensional gel electrophoretic analysis (Fig. 7).
The results with XPV extracts also confirmed that in these
experiments the left fork had insufficient time to proceed
around the plasmid, invade the the 2.9-kb fragment, and create
SF-containing molecules. Thus, the simultaneous detection of
the two SF arcs in association with the 4.5- and 2.9-kb frag-
ments signals the displacement of the right fork beyond the
nearby ClaI site and, by inference, the bypass of the T[c,s]T
dimer (Fig. 2B). Judging from the percentage of the total ra-
dioactivity that was found associated with these fork arcs,
bypass of the pyrimidine dimer during the 30-min incubation
occurred in approximately 46, 61, or 72% of the damaged mol-
ecules that were replicated by HeLa, IDH4, or XPA extracts,
respectively. Results from five independent experiments with
these three bypass-proficient extracts yielded an average of
63 6 14%. These results now clearly demonstrate that newly
replicated RFI DNA containing the T[c,s]T dimer (detected by
T4 endoV) was the product of dimer bypass by the replication
fork that first encountered the lesion (Fig. 2B). Bypass repli-
cation under our experimental conditions (#30 min) also ap-
pears to require the participation of a factor that is absent or
defective in extracts from XPV cells.
Further inspection of Figs. 6, C, F, and I, and 7B also reveals
the presence of labeled structures of higher molecular weights
than those discussed above. Their position in the two-dimen-
sional gels suggests a relationship with end-to-end molecules of
7.4-kb in size, i.e. replicating molecules that were not digested
by ClaI in all sites (Fig. 2). This incomplete digestion appeared
to be restricted to the replicating DNA (radiolabeled) because
ethidium bromide fluorescence of the gels prior to dehydration
allowed for the visualization of only the expected fragments of
plasmid DNA. The amount of radioactivity associated with the
partially restricted DNA was even higher when replication
intermediates were co-digested with AlwNI and EcoRI (Fig. 8,
B and C) but not as conspicuous when XmnI was used (Fig. 8,
E and F). We suspect that the secondary structure of DNA
around the blocked replication forks was not compatible with
complete cutting by EcoRI, ClaI, or other restriction enzymes
with recognition sites within 1.4 kb of the 59 side of the dimer.
This might have resulted from the proposed uncoupling of
leading and lagging strand synthesis in replication forks
blocked by a pyrimidine dimer (25), or an N-2-acetylaminoflu-
orene adduct (56, 57), thus generating long stretches of single-
stranded DNA beyond the template lesion. These results would
be consistent with the model depicted in Fig. 9A. Daughter-
strand gaps of 800–1250 nucleotides have been detected in
newly replicated DNA following UV irradiation of human cells
(58, 59). This model is supported by the results of two-dimen-
sional gel electrophoretic analyses showing predicted increases
in the amount of replication intermediates in bubble arcs (Fig.
9C) and decreases to control levels of the amount of replication
intermediates trapped in the 7.4-kb replication arc (Fig. 9D), as
the restriction digestion site is moved further downstream from
the pyrimidine dimer. The faint arc seen in Figs. 6I and 8, C
and F, at about the same position as the SF arc rising from the
large restriction fragment, could be due to breakage of the long
single-stranded DNA regions in the anomalous 7.4-kb replica-
tion intermediate.
DISCUSSION
The process of replication of DNA containing obstructive
lesions is poorly understood. Consequently, we lack clear and
precise terms to describe it. Structural alterations in template
DNA can be overcome during semi-conservative DNA synthesis
to generate fully replicated molecules still containing the pri-
mary lesion. This process is commonly denoted in the literature
as post-replication repair (PRR). Bypass replication is another
term that has been used in its broader sense as a synonym for
PRR or more narrowly to evoke a sub-set of proposed PRR
pathways (60). Neither of these two terms, however, conveys
information on how the replication machinery responds to le-
sions on template DNA or the mechanisms involved in the
replication of the damaged substrate.
We prefer to use the term bypass replication in its broad
sense as synonymous of PRR and have adopted the term rep-
lication fork bypass to connote the movement of the replication
machinery through and beyond the damaged site in template
DNA. In this study we have focused primarily on the effect of a
pyrimidine dimer (placed on the template for the leading
strand) on replication fork displacement and generation of com-
pletely replicated molecules. According to the model proposed
by Meneghini and Hanawalt (11), an UV-induced pyrimidine
dimer in the template for the leading strand (growing in the
593 39 direction) temporarily blocks DNA synthesis and fork
movement. If the dimer is instead in the template for the
FIG. 5. Two-dimensional gel electrophoresis of intermediates
of in vitro DNA replication after digestion with different restric-
tion enzymes. M13leaSV contains a single recognition site for AlwNI
at approximately 180° from the center of the SV40 origin (Fig. 1).
Control molecules (A, C, and E–G) or T[c,s]T-containing molecules (B
and D) were incubated for 30 min with extracts from HeLa (A and B) or
CTag (C–G). The purified DNA was digested with AlwNI (A–D), NcoI
(E), EcoRI (F), or PacI (G) and fractionated by two-dimensional electro-
phoresis, as described under “Methods.” Each one of these enzymes has
a single restriction site in M13leaSV (Fig. 1). Thus, the digestion of
replicating M13leaSV molecules with these enzymes generates sym-
metric bubbles (AlwNI), symmetric double forks (NcoI), or asymmetric
double forks (EcoRI, PacI). In a number of replicating molecules the left
fork had not yet reached the PacI site; therefore, in G one can clearly
identify the lower part of a bubble arc, as well as the top part of the
asymmetric double fork arc. Illustrations were prepared directly from
converted image files. In H we show schematically a comparison of the
relative positions of symmetric bubble (A) and double fork (E) arcs
generated from the same population of replication intermediates.
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lagging strand (growing discontinuously in the 393 59 direc-
tion), a long-lived daughter-strand gap is generated following
the interruption of a single Okazaki fragment (61). The lagging
strand gaps are eventually filled in by mechanisms that could
be operating away from the replication fork. The nature of the
protein complexes that catalyze this process is unclear at this
time. Gap-filling repair via homologous recombination has
been difficult to prove or to discount as an important PRR
mechanism in human cells (60). Alternatively, the gaps are
closed in by de novo synthesis (58) with factors that may or may
not be regular components of the enzymatic machinery associ-
ated with replication forks.
The experiments reported here were planned with two goals
in mind. We wished to establish whether bypass replication of
pyrimidine dimers in human cells occurred concurrently with
replication fork movement beyond the lesion (Fig. 2B). We were
also interested in determining whether PRR-defective XPV
cells are deficient in bypass replication of CPDs. After creating
an immortalized XPV cell line (CTag) and preparing competent
extracts for in vitro replication (44), we determined that the
synthesis of RFI DNA (Fig. 3) from molecules containing a
single T[c,s]T dimer (Fig. 1) was inhibited by 73% when XPV
extracts were used or 2.6-fold more strongly than when HeLa
extracts replicated the same plasmid. Furthermore, the RFI
molecules synthesized by XPV extracts were devoid of T4 en-
doV-sensitive sites (Fig. 3 and Table I), suggesting that XPV
extracts did not support detectable levels of CPD bypass repli-
cation. These results were in sharp contrast to those obtained
with extracts from PRR-proficient cells (Figs. 3 and 4).
Two-dimensional gel electrophoresis of intermediates of
DNA replication has proven to be a very powerful technique for
mapping and characterizing origins of DNA replication (53, 54,
62, 63). Because the behavior in two-dimensional gels of DNA
molecules containing branches and bubbles has been charac-
terized, this technique is well-suited for determining the effect
of a site-specific CPD on the progression of replication forks
along circular duplex DNA molecules. The results depicted in
Figs. 5–8 show clearly that the patterns of replication inter-
mediates observed by two-dimensional gel analyses were con-
sistent with that expected from the map in Fig. 1. For instance,
bubble arcs were observed only in association with restriction
fragments containing the SV40 origin of replication, whereas
distal fragments displayed the presence of single fork arcs.
Kinetic experiments and two-dimensional gel analysis of rep-
lication products digested with AlwNI (Fig. 5) established that
30 min was insufficient time for the left replication fork to
travel around the circular DNA and approach the dimer from
downstream sequences. Figs. 6–8 show single fork arcs that
herald the replication of restriction enzyme recognition sites
located further away from the SV40 origin of replication than
the pyrimidine dimer (Fig. 1). These results constitute very
strong evidence that the right fork progressed beyond the
dimer, thus demonstrating replication fork bypass.
HeLa extracts and those prepared from SV40-transformed
FIG. 6. Two-dimensional agarose
gel electrophoresis analyses of repli-
cation intermediates digested with
ClaI. Extracts from HeLa (A–C), IDH4 (E
and F), or CTag (G–I), in the presence (B,
C, E, F, H, and I) or absence (A and G) of
Tag, were incubated for 30 min with con-
trol DNA (A, B, E, G, and H) or DNA
carrying the single T[c,s]T dimer (C, F,
and I). The purified DNA was digested
with ClaI and separated by two-dimen-
sional gel electrophoresis. The position of
the 4.5-kb linear fragment is indicated in
all panels with an arrow; the arcs of rep-
licating intermediates associated with the
4.5- and 2.9-kb fragments are identified
in D. The arcs identified by the open tri-
angles in C, F, and I are discussed in the
text.
FIG. 7. Extract of NER-deficient cells displays capability for
replication fork bypass of a pyrimidine dimer. Control molecules
(A) or T[c,s]T-containing molecules (B) were replicated in vitro with an
extract of SV40-transformed XPA cells, under the conditions described
under “Methods.” The purified DNA was restricted with ClaI and ana-
lyzed as described in Fig. 6.
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human fibroblasts (IDH4, SV80) were equally competent for
bypass replication of pyrimidine dimers (Figs. 6 and 8). This
proficiency was not related to the presence or absence of NER
activity. Extracts from XPA cells were competent for replica-
tion fork bypass (Fig. 7), and the dimer was found in molecules
replicated by extracts from non-XPV cells (Figs. 3 and 4; Table
I). Therefore, NER did not precede replication fork bypass.
Results with immortalized human fibroblasts demonstrated
that the capability for bypass replication detected in HeLa
extracts (this report; Refs. 23–26) was not peculiar to these
malignant cells but instead a characteristic of the replication of
UV-damaged DNA in humans. The lack of bypass replication in
XPV extracts was not related to the immortalization of the XPV
cells by Tag, as IDH4, SV80, and XPA cells were immortalized
with the same oncoprotein. Finally, detection of replication fork
movement beyond the T[c,s]T dimer by two-dimensional gel
electrophoresis and quantification of the percentage of replicat-
ing molecules (63 6 14%) in which this bypass was accom-
plished within the first 30 min of in vitro incubation demon-
strated for the first time that bypass replication occurs
concomitantly with replication fork bypass, presumably by a
mechanism that permits the elongation of the leading strand
blocked by the dimer (see below).
In the human cell extracts used in this study, the DNA
replication machinery was arrested by the T[c,s]T dimer found
in the template for the leading strand. This arrest was tempo-
rary in molecules replicated by extracts proficient in bypass
replication, and it was followed by movement of the replication
fork beyond the pyrimidine dimer. It was the appearance of an
anomalous arc of replicating structures of higher molecular
weight (1 3 5 7.4 kb) than those expected to be associated with
restriction fragments (Figs. 6–8) that suggested to us that the
presence of the T[c,s]T dimer in the template for the leading
strand was affecting the progression of the replication fork in a
very peculiar way. Until recently, our working model of an
active replication fork depicted the leading strand synthesis
spearheading the opening of the replication fork and the dis-
continuous synthesis of the complementary strand “lagging”
behind. Thus, we expected that blocking of leading strand
synthesis by the T[c,s]T dimer would automatically halt the
displacement of the replication fork. Consequently, we pre-
dicted that after digestion of products of in vitro replication on
the damaged substrate with EcoRI (together with AlwNI),
ClaI, or XmnI, a larger fraction of the radioactivity associated
with replication intermediates would be found in the bubble
arc, in comparison to undamaged controls. This prediction was
only partially fulfilled by the results shown in Fig. 9C. The
restriction fragment containing the SV40 origin of replication
displayed a more prominent bubble arc as the restriction en-
zyme digestion site was moved further away from the origin in
the undamaged substrate molecule. Likewise, when the
T[c,s]T-containing substrate was replicated by extracts defi-
cient or proficient in bypass replication, the relative represen-
tation of the bubble arc was increased upon digestion with ClaI
or XmnI. We were surprised, however, that when products of
replication of the T[c,s]T-containing plasmid were restricted
with EcoRI, the bubble arc was barely detectable (Fig. 9C) and
instead a strong radioactive signal was found in association
with the 7.4-kb replication arc (Fig. 9D). Since the 1 3 size of
the molecules forming this 7.4-kb arc was exactly the genome
size of M13leaSV, it was likely that in a fraction of replication
intermediates only one of the two EcoRI sites within the rep-
lication bubble had been cut (Fig. 9B). Furthermore, the shape
of the arc strongly suggested branched molecules instead of
bubble-containing molecules (Fig. 5). These observations, to-
gether with those in the literature suggesting that lagging
strand synthesis becomes uncoupled from leading strand syn-
thesis upon encountering a DNA lesion in the template for the
leading strand (25, 56, 57), are best explained by the model
illustrated in Fig. 9B. The salient characteristics of this model
are as follows: (i) the fork structure created by the gradual
melting of the duplex DNA, presumably through the activities
of DNA helicases and topoisomerases, is followed closely be-
hind by the priming and elongation of the next Okazaki frag-
ment of the lagging strand; (ii) elongation of the leading strand
occurs simultaneously, but its 39 growing end is found at se-
quences preceding those already initiated in the lagging strand
(64); (iii) upon blocking of leading strand elongation by the
dimer, priming and synthesis of the lagging strand continues to
open up the fork before its movement is stalled. Consequently,
a stretch of template for the leading strand is left as single-
stranded DNA that cannot be digested by restriction endo-
nucleases. Cutting the replicating molecules at ;180° from the
origin and on the lagging strand side of the extended replica-
tion bubble would generate branched molecules expected to
migrate in the two-dimensional gels as the 7.4-kb replication
arc. The results depicted in Fig. 9D seem to suggest that the
single-stranded template DNA at the replication fork might
extend ;700–1400 nucleotides beyond the dimer. These lower
and upper limits are suggested by the still large radioactive
FIG. 8. Probing the structure of replication intermediates with other restriction endonucleases. Products of in vitro DNA replication
of control molecules (A and D) or T[c,s]T-containing molecules (B, C, E, and F) with extracts from HeLa (A, B, D, and E) or CTag (C and F) were
digested with both EcoRI and AlwNI (A–C) or with XmnI (D–F) and analyzed by two-dimensional gel electrophoresis. Results with HeLa or CTag
extracts were indistinguishable when control molecules were used. Thus, the CTag controls were omitted from the illustration. The triangles point
to the 7.4-kb replication intermediate arc (see text).
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signal associated with the 7.4-kb intermediate in replication
products digested with ClaI, which dropped to control levels
(especially in bypass-proficient cells) when DNA was digested
with XmnI (Fig. 9D). These interpretations are also strongly
supported by results of the size and frequency of daughter-
strand gaps in irradiated human cells, as measured by the
estimated target size of S1 nuclease-sensitive sequences in
DNA replicated after UV (59). It was found that 65% of these
daughter-stranded gaps (single-stranded template regions) cor-
responded to stretches of 1250 nucleotides and 35% to stretches
of 150 nucleotides. The smaller class is thought to represent
gaps formed in the lagging strand by the interruption of an
Okazaki fragment (59, 61). We now submit that the larger class
represents single-stranded regions of DNA template created by
blocking of leading strand synthesis by the dimer and uncou-
pling of lagging strand synthesis (25, 56, 57).
Having discussed the evidence for replication fork bypass of
pyrimidine dimers in humans and the implication that the
extension of the blocked leading strand is catalyzed by enzyme
activities associated with the replication fork, it remains to be
determined by which mechanism this occurs. Two formal pos-
sibilities can be envisioned at this time, mainly trans-lesion
synthesis or strand switching. O’Day et al. (14) have shown
that proliferating cell nuclear antigen facilitates trans-dimer
bypass by DNA polymerase d on a primed single-stranded
oligonucleotide. More recently, DNA polymerase j has been
discovered in yeast and shown by in vitro assays to catalyze
trans-dimer synthesis very efficiently (15). It is assumed that
these polymerases and accessory proteins operating as compo-
nents of active DNA replication complexes should be capable of
trans-dimer synthesis in vitro and in vivo. In this regard, it is
noteworthy that a mutation in proliferating cell nuclear anti-
gen has been associated with defective RAD6-dependent PRR
(error-free bypass) of UV-damaged DNA (65). Furthermore,
bulky lesions that block DNA synthesis on single-stranded
template were bypassed in vitro when placed in fork-like DNA
and incubated with extracts from HeLa or Chinese hamster
ovary cells (66).
An alternative mechanism calls for the extension of the
blocked leading strand after annealing of its 39 end to the newly
synthesized lagging strand that is identical in sequence and
polarity to the damaged template. Such a template-switching
mechanism, originally proposed by Higgins et al. (67) and Fugi-
wara and Tatsumi (68), could represent a caffeine-resistant
pathway of PRR (31, 32, 68). Evidence supporting the uncou-
pling of leading and lagging strand synthesis (25, 56, 57, this
report) and the possibility that the newly synthesized lagging
strand could be extended by more than 1000 nucleotides be-
yond the dimer give new credence to the template-switching
pathway. Furthermore, it is expected that copying of the un-
damaged lagging strand could be done at a much higher degree
of fidelity than carrying out trans-lesion synthesis. Inactiva-
tion of this pathway may explain the XPV’s defect in PRR (8,
31, 34), UV hypermutability (39–43), abnormal sensitivity to
caffeine (31, 32, 68), and the deficiency in replication fork
bypass described here.
In conclusion, our findings and those reported by others
suggest that the XPV phenotype is related to the loss (or
alteration) of a gene product that facilitates the relatively fast
bypass of the pyrimidine dimer, perhaps through a template-
switching mechanism or another error-free mechanism of by-
pass replication of pyrimidine dimers. However, if this gene
product is a normal component of the DNA replication machin-
ery, the XPV mutation does not appear to interfere with the
replication of undamaged DNA. Finally, we suspect that the
absence of a relatively fast mechanism for dimer bypass by
replication forks leads to a prolonged arrest of replication at the
photoproduct in XPV, interference with the removal of these
DNA lesions by NER, and an increase in the probability of
structural modifications of the dimer, such as deamination of
cytosines (69, 70). When the replication machinery eventually
overcomes the block, the ensuing trans-lesion synthesis, as the
only option for bypass replication in XPV, would be associated
with a high probability of base-substitution mutations.
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